Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca, MRC Establish R&D Fund

by Lisa M. Jarvis
May 26, 2014 | A version of this story appeared in Volume 92, Issue 21

AstraZeneca and the U.K. Medical Research Council Laboratory of Molecular Biology have established a joint fund to support drug discovery projects. AstraZeneca has committed up to $10 million and MRC up to $5 million over five years. The fund will support preclinical research projects conducted by AstraZeneca and MRC scientists. It’s the latest in a string of developments between AstraZeneca and MRC; earlier this year the partners announced plans to establish a joint research facility in AstraZeneca’s new Cambridge, England, R&D headquarters.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.